Cargando…

IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer

Chronic obstructive pulmonary disease (COPD) is associated with neutrophilic lung inflammation and CD8 T cell exhaustion and is an important risk factor for the development of non-small cell lung cancer (NSCLC). The clinical response to programmed cell death-1 (PD-1) blockade in NSCLC patients is va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ritzmann, Felix, Jungnickel, Christopher, Vella, Giovanna, Kamyschnikow, Andreas, Herr, Christian, Li, Dong, Menger, Michael M., Angenendt, Adrian, Hoth, Markus, Lis, Annette, Bals, Robert, Beisswenger, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637115/ https://www.ncbi.nlm.nih.gov/pubmed/31316109 http://dx.doi.org/10.1038/s41598-019-46759-8

Ejemplares similares

The IL-17 receptor IL-17RE mediates polyIC-induced exacerbation of experimental allergic asthma
por: Vella, Giovanna, et al.
Publicado: (2020)

IL-17C contributes to NTHi-induced inflammation and lung damage in experimental COPD and is present in sputum during acute exacerbations
por: Vella, Giovanna, et al.
Publicado: (2021)

IL-17 Cytokines and Chronic Lung Diseases
por: Ritzmann, Felix, et al.
Publicado: (2022)

Moxifloxacin modulates inflammation during murine pneumonia
por: Beisswenger, Christoph, et al.
Publicado: (2014)

Cigarette smoke-promoted acquisition of bacterial pathogens in the upper respiratory tract leads to enhanced inflammation in mice
por: Voss, Meike, et al.
Publicado: (2015)

Interaction of allergic airway inflammation and innate immunity: hygiene and beyond
por: Beisswenger, Christoph, et al.
Publicado: (2008)

IL-17C and IL-17RE Promote Wound Closure in a Staphylococcus aureus-Based Murine Wound Infection Model
por: Pätzold, Linda, et al.
Publicado: (2021)

STIM-Orai Channels and Reactive Oxygen Species in the Tumor Microenvironment
por: Frisch, Janina, et al.
Publicado: (2019)

Flagellin shifts 3D bronchospheres towards mucus hyperproduction
por: Sprott, Richard F., et al.
Publicado: (2020)

Faster cytotoxicity with age: Increased perforin and granzyme levels in cytotoxic CD8 (+) T cells boost cancer cell elimination
por: Zöphel, Dorina, et al.
Publicado: (2022)

The composition of the pulmonary microbiota in sarcoidosis – an observational study
por: Becker, André, et al.
Publicado: (2019)

Receptor for advanced glycation endproducts (RAGE) maintains pulmonary structure and regulates the response to cigarette smoke
por: Wolf, Lisa, et al.
Publicado: (2017)

Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer
por: Wang, Man-Tzu, et al.
Publicado: (2019)

Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors
por: Jiang, Honglin, et al.
Publicado: (2022)

An In Vivo Inflammatory Loop Potentiates KRAS Blockade
por: Arendt, Kristina A. M., et al.
Publicado: (2022)

Therapeutic Application of Alpha-1 Antitrypsin in COVID-19
por: Ritzmann, Felix, et al.
Publicado: (2021)

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
por: Konen, Jessica M., et al.
Publicado: (2019)

PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease
por: Duhalde Vega, Maite, et al.
Publicado: (2022)

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
por: Tang, Daolin, et al.
Publicado: (2021)

Iron out KRAS-driven cancer
por: Lei, Guang, et al.
Publicado: (2022)

G6PD Maintains Redox Homeostasis and Biosynthesis in LKB1-Deficient KRAS-Driven Lung Cancer
por: Lan, Taijin, et al.
Publicado: (2023)

Cigarette smoke and electronic cigarettes differentially activate bronchial epithelial cells
por: Herr, Christian, et al.
Publicado: (2020)

Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
por: Kwack, Won Gun, et al.
Publicado: (2020)

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure
por: Shin, Daniel, et al.
Publicado: (2015)

KRAS-driven ROS promote malignant transformation
por: Suh, Yongjoon, et al.
Publicado: (2015)

Twists and turns in Kras-driven tumor initiation
por: Maru, Yoshiaki, et al.
Publicado: (2021)

Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade
por: Velu, Vijayakumar, et al.
Publicado: (2008)

Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8(+) T Cells
por: Baraibar, Iosune, et al.
Publicado: (2020)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Orai, STIM, and PMCA contribute to reduced calcium signal generation in CD8(+) T cells of elderly mice
por: Angenendt, Adrian, et al.
Publicado: (2020)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
por: Arner, Emily N., et al.
Publicado: (2019)

Brown Tumors Belong to the Spectrum of KRAS-driven Neoplasms
por: Turek, Daniel, et al.
Publicado: (2022)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Th17 blockade reduces the itch
por: Bashyam, Hema, et al.
Publicado: (2007)

Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity
por: Lee, Jungeun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4kgjitmtdruaaohqg0lv51mbf3